We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Sheffield NHS Lab Moves to Advanced Micorarrays Platform

By LabMedica International staff writers
Posted on 08 Feb 2015
Print article
A case study discusses Sheffield laboratory’s experience of switching to a more efficient and reliable microarrays platform for cytogenetic research.

Advances in array design and analysis capabilities mean that choosing a platform can be challenging. A new case study by Oxford Gene Technology (OGT; Oxfordshire, UK) explores how Sheffield Children's NHS Foundation Trust (UK) has seamlessly transferred to its CytoSure ISCA 8x60k platform. Upon a highly stringent National Health Service (NHS, UK) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. It was the only platform able to correctly identify all the genetic abnormalities tested.

The NHS carried out a comprehensive comparison of multiple array platforms in order to select the most effective solution (considering quality of results, ease of use and cost) via a consortium led by four prominent laboratories. Chosen over alternatives, the success of the CytoSure ISCA array, designed in partnership with the International Collaboration for Clinical Genomics (ICCG), was attributed to a combination of the array and CytoSure Interpret Software performance. Every lab submitted a set of challenging samples to be processed by OGT, and the results came back clean and clear, with the data interpretation software greatly facilitating analysis.

Maintaining productivity within the laboratory, OGT worked hard to ensure a seamless transfer process. In addition to getting the new system itself up and running, the team also provided on-site operational training, software tutorials, and transfer of local legacy data to the CytoSure Interpret Software database. “I can only be extremely positive about the whole process of switching to OGT’s CytoSure platform, so if anyone asks me if it’s worth the time and effort of transferring, the answer is a clear yes,” said Kath Smith, consultant clinical scientist at Sheffield’s. James Clough, Executive Vice President Commercial at OGT, commented, “It’s a pleasure to welcome Sheffield Children's NHS Foundation Trust to OGT. Customer satisfaction is extremely important to us, so it’s great to get such positive feedback on our products and support. It’s a testament to our team’s hard work and dedication.”

A 3 month data audit has revealed more accurate aneuploidy calling, leading to fewer uncertain cases and saving time and resources involved in follow-up investigations. The switch has also benefited Sheffield’s lab from the practicality of high-throughput plate-based labeling through to enhancing its overall operation in a more cost-effective manner.

CytoSure is provided under an agreement between Agilent Technologies and OGT. The product is for research use only and not for diagnostic or other medical use.

Related Links:

Oxford Gene Technology
Evaluating and switching to CytoSure microarrays, OGT case study 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Food Allergens Assay Kit
Allerquant 14G A
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.